BRCA1 tumours | BRCA2 tumours | Non-BRCA1/2 tumours | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age <50 | Age ≥ 50 | P < 0.05a | Age <50 | Age ≥ 50 | P < 0.05a | Age <50 | Age ≥ 50 | P < 0.05a | |||||||
Histology | |||||||||||||||
Ductal cancer | 24 | (70.6) | 13 | (76.5) | 19 | (54.3) | 18 | (75.0) | 34 | (58.6) | 68 | (72.3) | |||
Lobular cancer | 5 | (14.7) | 3 | (17.6) | 12 | (34.3) | 5 | (20.8) | 15 | (25.9) | 15 | (16.0) | |||
Medullary cancer | 5 | (14.7) | 2 | (3.4) | 1 | (1.1) | |||||||||
Other cancers | 1 | (5.9) | 4 | (11.4) | 1 | (4.2) | 7 | (12.1) | 10 | (10.6) | |||||
Grade | |||||||||||||||
I | 1 | (3.1) | 2 | (11.8) | 7 | (23.3) | 5 | (22.7) | 13 | (25.0) | 33 | (36.7) | |||
II | 4 | (12.5) | 7 | (41.2) | 16 | (53.3) | 10 | (45.5) | 30 | (57.7) | 36 | (40.0) | |||
III | 27 | (84.4) | 8 | (47.1) | 0.009 | 7 | (23.3) | 7 | (31.8) | 9 | (17.3) | 21 | (23.3) | ||
I to II | 5 | (16.6) | 9 | (53.0) | 13 | (76.7) | 15 | (68.2) | 43 | (82.7) | 69 | (76.7) | |||
Immunohistochemistry | |||||||||||||||
ER- | 25 | (83.3) | 3 | (25.0) | 0.001 | 7 | (20.6) | 10 | (52.6) | 0.017 | 17 | (29.3) | 23 | (25.6) | |
ER+ | 5 | (16.7) | 9 | (75.0) | 27 | (79.4) | 9 | (47.4) | 41 | (70.7) | 67 | (74.7) | |||
PR- | 28 | (90.3) | 9 | (69.2) | 12 | (35.3) | 16 | (80.0) | 0.001 | 18 | (31.0) | 49 | (54.4) | ||
PR+ | 3 | (9.7) | 4 | (30.8) | 22 | (64.7) | 4 | (20.0) | 40 | (69.0) | 41 | (45.6) | |||
p53- | 15 | (50.0) | 12 | (92.3) | 0.014 | 27 | (81.8) | 15 | (83.3) | 43 | (74.1) | 75 | (81.5) | ||
p53+ | 15 | (50.0) | 1 | (7.7) | 6 | (18.2) | 3 | (16.7) | 15 | (25.9) | 17 | (18.5) | |||
ERBB2- | 23 | (76.7) | 12 | (92.3) | 29 | (83.3) | 16 | (84.2) | 45 | (81.8) | 64 | (83.1) | |||
ERBB2+ | 7 | (23.3) | 1 | (7.7) | 5 | (14.7) | 3 | (15.8) | 10 | (18.2) | 13 | (16.9) |